Unternehmens-Analyse: BASF

Zusammenfassung

BASF SE (ticker: BASF / BAS.DE) is a diversified chemicals producer organized around an integrated “Verbund” production model (shared feedstocks, utilities, and logistics) and a portfolio spanning Chemicals, Materials, Industrial Solutions, Surface Technologies, Nutrition & Care, and Agricultural Solutions. Core competencies include large-scale process chemistry, integrated asset utilization, formulation know-how (e.g., dispersions/resins, care ingredients), and a global manufacturing and distribution footprint. The business is highly cyclical and sensitive to energy/feedstock costs, industrial demand, and pricing spreads. Market position remains that of a global scale leader in chemicals with meaningful European manufacturing exposure (notably Ludwigshafen) and a differentiated earnings contributor in Agricultural Solutions. Management continues to emphasize structural cost reduction and portfolio actions to improve resilience. BASF reiterates it is on track to deliver ~€2.1bn total cost savings by end-2026, including measures at the Ludwigshafen site. (basf.com) Recent developments (last ~90 days) are dominated by FY2025 reporting and 2026 guidance. BASF published FY2025 results on February 27, 2026 and guided 2026 EBITDA before special items to €6.2–€7.0bn (vs. €6.6bn in 2025), implying a broadly stable earnings base with a wide range reflecting macro and spread uncertainty. (basf.com) BASF also proposed a €2.25/share dividend, with the AGM scheduled for April 30, 2026 and payment expected May 6, 2026 (subject to approval). (basf.com) Preliminary FY2025 figures (Jan 22, 2026) indicated sales of ~€59.7bn and EBITDA before special items of ~€6.6bn, slightly below the company’s prior range and near/just below analyst averages cited by BASF. (basf.com) Key financial metrics are mixed due to earnings normalization and special items: FY2025 sales were ~€59.7bn and EBITDA before special items €6.6bn; free cash flow improved versus 2024, supported by lower capex. (basf.com) Reported valuation multiples vary materially by data provider and earnings definition; trailing P/E screens for BASF can appear elevated/unstable in some datasets, so investors should anchor on normalized earnings and forward estimates rather than a single headline P/E. (companiesmarketcap.com) Outlook: In the short term (next 3–6 months), the stock is likely to be driven by Q1 2026 results (scheduled April 30, 2026) and any revisions to the 2026 EBITDA range, plus evidence that pricing actions and cost savings are translating into margins. (chartmill.com) Medium term (6–18 months), the investment case hinges on (1) delivery of the 2026 cost-savings program, (2) chemical demand recovery trajectory into late 2026/2027, and (3) capital discipline and cash conversion supporting dividends and balance sheet stability. (basf.com)

Key Takeaways

1. FY2025 results show a subdued earnings base: ~€59.7bn sales and €6.6bn EBITDA before special items, with improved free cash flow supported by lower capex. (basf.com)
2. 2026 guidance implies broadly stable earnings but with a wide uncertainty band: EBITDA before special items €6.2–€7.0bn. (basf.com)
3. Management’s cost program is a central lever: BASF targets ~€2.1bn total cost savings by end-2026, including Ludwigshafen measures. (basf.com)
4. Dividend remains a key part of the equity story: €2.25/share proposed, with AGM April 30, 2026 and expected payment May 6, 2026 (subject to approval). (basf.com)
5. Headline valuation metrics are noisy across providers due to earnings/special items; investors should triangulate using forward estimates and cash-flow-based measures rather than relying on a single trailing P/E screen. (companiesmarketcap.com)

Action-Ideen

Contrarian Insights

• • Consensus often frames BASF primarily as a Europe-energy-cost problem; a contrarian framing is that the cost-savings program (~€2.1bn by end-2026) is large enough to be a first-order driver of margin normalization even without a strong volume rebound—meaning execution quality may matter as much as macro. (basf.com)
• • Headline P/E screens can look extreme or contradictory across providers; a contrarian (but disciplined) approach is to de-emphasize trailing P/E entirely and focus on (i) EBITDA-before-special-items guidance, (ii) cash flow after capex, and (iii) balance sheet trajectory—metrics BASF explicitly guides and reports. (basf.com)